The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kobayashi Kako to Withdraw Marketing License on April 1
Over two years after a high-profile sleep-inducer contamination scandal, Kobayashi Kako will discontinue its operations as a pharmaceutical marketing authorization (MA) holder, as of April 1. The generic maker said on March 22 that it will delist all products registered…
To read the full story
Related Article
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai
December 7, 2021
- Kobayashi Kako Slapped with Record 116-Day Business Suspension
February 9, 2021
BUSINESS
- Daiichi Begins Global PIII of Enhertu in Adjuvant Endometrial Cancer Use
December 23, 2025
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…